Oktarina, Dyah Ayu Mira
Department Of Dermatology And Venereology, Faculty Of Medicine, Public Health, And Nursing, Universitas Gadjah Mada/Dr Sardjito Hospital, Yogyakarta

Published : 6 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 6 Documents
Search

Effect of freeze-drying process of collagen-activated platelet-rich plasma on transforming growth factor-β1 level Kwartarini Murdiastuti; Fitri Yuniawati; Dahlia Herawati; Nunuk Purwanti; Dyah Ayu Mira Oktarina
Majalah Kedokteran Gigi Indonesia Vol 5, No 2 (2019): August
Publisher : Faculty of Dentistry, Universitas Gadjah Mada

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.22146/majkedgiind.40197

Abstract

Periodontal tissue damage requires regenerative material to repair the damage. Platelet-rich plasma (PRP) is known as a regenerative material from blood which contains high level of growth factor that plays a role in wound healing and tissue remodeling. However PRP has a weakness, i.e. it is too watery so it is easily dissolved in the oral cavity, and should be used immediately after preparation. Therefore PRP storage method is needed to increase the benefits of PRP. The addition of collagen to PRP serves as a scaffold as well as an activator that stimulates the release of growth factors. One method of storing PRP is by freeze-drying process. The purpose of this study was to analyze the effect of freeze-drying process of collagen-activated PRP (PRP+C) on transforming growth factor-β1 (TGF-β1) levels. Transforming growth factor-β1 is a cytokine content in PRP, that plays a role in bone remodeling and is an important stimulator for osteoblast formation, causing chemotaxis, osteoblast proliferation and differentiation. In this study, PRP was produced from peripheral blood probandus. Platelet-rich plasma was then activated with collagen (PRP+C), and divided into two groups: freeze-dried PRP collagen (FD PRP+C); and non freeze-dried PRP+collagen (PRP+C). Transforming growth factor-β1 levels were measured using the ELISA method, followed by independent t-test. The TGF-B1 level of FD PRP+C group was significantly higher than PRP+C group (p<0.05). From this study it can be concluded that freeze-dried collagen-activated PRP has an effect to increase TGF-β1 level.
Association between HLA-B alleles and nevirapine-induced allergies among Indonesian HIV patients Angela Satiti Retno Pudjiati; Dyah Ayu Mira Oktarina; Hardyanto Soebono; Saihas Sauda; Dewi Kartikawati Paramita; Iwan Dwiprahasto; Zubairi Djoerban
Journal of the Medical Sciences (Berkala Ilmu Kedokteran) Vol 48, No 4 (2016)
Publisher : Journal of the Medical Sciences (Berkala Ilmu Kedokteran)

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (367.093 KB) | DOI: 10.19106/JMedSci004804201604

Abstract

This study aimed to investigate the association between human leukocyte antigen-B(HLA-B) alleles and nevirapine allergy in HIV patients in Indonesia. A case control studywas conducted involving 147 HIV patients comprising of 50 patients with and 97patients without nevirapine allergy as control. The HLA-B allele typing was conducted byusing polymerase chain reaction-sequence specific oligonucleotide probes (PCR-SSOP),followed by sequencing. Bivariate analysis using Chi-square (X2) test and multivariatelogistic regression with significance level at p<0.05 were applied to analysis the data.Among 147 subjects, 34 with HLA-B alleles were identified. Bivariable analysis showedthat HLA-B*58 allele was the most significant risk factor for the nevirapine allergy (OR= 3.67; 95% CI: 1.79 to 7.54), while HLA-B*35 allele was a protective factor (OR =0.18; 95% CI: 0.08 to 0.42). Multivariate logistic regression analysis showed that youngmen and HLA-B*58 allele were the significant risk factors of nevirapine allergy (OR: 4.63;95% CI: 2.02 to 10.61), while older women with the HLA-B*35 was able to reducethe risk of nevirapine allergy approximately 81% (OR: 0.19; 95% CI: 0.08 to 0.49). Inconclusion, young male with the HLA-B*58 allele are the high risk factor for nevirapineallergy in Indonesian HIV patients.
Pseudolimfoma Kutis: Laporan Kasus Kartika Kemala; Wening Setyani; Dyah Ayu Mira Oktarina; Yohanes Widodo Wirohadidjojo
Berkala Ilmu Kesehatan Kulit dan Kelamin Vol. 30 No. 3 (2018): DESEMBER
Publisher : Faculty of Medicine, Universitas Airlangga

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (525.073 KB) | DOI: 10.20473/bikk.V30.3.2018.275-278

Abstract

Latar Belakang: Pseudolimfoma kutis adalah proses limfoproliferatif jinak poliklonal pada kulit, yang menyerupai limfoma kutis secara klinis dan atau histopatologi. Pseudolimfoma kutis bermanifestasi dalam bentuk nodul atau plak keunguan pada wajah. Pada kasus yang dicurigai sebagai pseudolimfoma kutis, bagian terpenting adalah diagnosis untuk membedakan lesi tersebut jinak atau ganas. Diagnosis memerlukan kombinasi antara pemeriksaan klinis, histopatologis, dan imunohistokimia. Tujuan: Melaporkan satu kasus pseudolimfoma kutis yang menitikberatkan pada masalah penegakan diagnosis. Kasus: Seorang wanita usia 27 tahun, datang dengan keluhan nodul asimptomatik berwarna merah pada pipi sejak 2 bulan yang lalu. Pemeriksaan histopatologi didapatkan sebukan limfosit padat membentuk folikel limfoid dengan centrum germinativum yang sebagian mendestruksi kelenjar appendices kulit dan meluas hingga jaringan lemak subkutis. Pemeriksaan imunohistokimia menunjukkan hasil positif dengan pewarnaan cluster of differentiation (CD) 20+, CD3+, dengan dominasi pada CD3+. Pewarnaan CD4+ menunjukkan hasil positif dan CD8+ dengan hasil negatif. Penatalaksanaan: Pasien diterapi dengan injeksi triamsinolon asetonid 10 mg/ml intralesi, dan memberikan hasil yang memuaskan setelah 3 kali injeksi. Simpulan: Berdasarkan anamnesis, pemeriksaan fisik, pemeriksaan histopatologi, dan imunohistokimia, telah ditegakkan kasus pseudolimfoma kutis pada seorang wanita 27 tahun. Terapi dengan injeksi triamsinolon asetonid 10 mg/ml intralesi memberikan hasil yang memuaskan.
The Role of Connexin in Cutaneous Adverse Drug Reactions (CADRs) in Patients with Increasing Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT) Dyah Ayu Mira Oktarina; Gilang Baswara; Hardyanto Soebono
Berkala Ilmu Kesehatan Kulit dan Kelamin Vol. 33 No. 2 (2021): AUGUST
Publisher : Faculty of Medicine, Universitas Airlangga

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.20473/bikk.V33.2.2021.123-128

Abstract

Background: The occurrence of Cutaneous Adverse Drug Reactions (CADRs) is relatively rare but can be fatal when causing organ failure, especially in the liver. The supporting examinations to determine liver injury are aspartate aminotransferase (AST) and alanine aminotransferase (ALT). Connexin-32 (Cx32) and connexin-43 (Cx43) are gap junction proteins that can be found in the liver and allegedly have a role in the mechanism of liver injury. To date, correlations between the level of connexin and aminotransferases enzyme in humans with CADRs cases are still unclear. Purpose: To determine the correlations between Cx32/Cx43 and AST/ALT levels in CADRs cases. Methods: This was a retrospective study, data collected from inpatient and outpatient’s medical records, Department of Dermatology and Venereology of Dr. Sardjito Hospital, from 2011–2015. Result: A total of 25 patients with CADRs and 35 healthy controls were included in this study. The levels between Cx32 and AST, Cx32 and ALT, Cx43 and AST, and Cx43 and ALT were not significantly correlated in CADRs cases (p>0.05). Both Cx32 and Cx43 were not significantly different between patients with and without CADRs (p>0.05). Confounding factors such as gender were not associated with this study (p>0.05). Conclusion: There was no correlation between levels of Cx32/Cx43 and increasing AST/ALT in CADRs cases. Therefore, further study is necessary to conclude the correlation between connexin and aminotransferase enzyme in CADRs patients.
A Five-Year Review of Adverse Cutaneous Drug Reaction in a Tertiary Care Hospital in Yogyakarta, Indonesia Dyah Ayu Mira Oktarina; Maria Sophiati; Erinda Maharani Rambu Moha; Fajar Waskito; Hardyanto Soebono
Berkala Ilmu Kesehatan Kulit dan Kelamin Vol. 33 No. 3 (2021): DECEMBER
Publisher : Faculty of Medicine, Universitas Airlangga

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.20473/bikk.V33.3.2021.150-155

Abstract

Background: The prevalence of adverse drug reactions is likely to increase, and it is associated with increased usage of various drugs. Adverse Cutaneous Drug Reaction (ACDR) is the most frequent adverse drug reaction (30–45%). In Indonesia, the study on the prevalence of ACDR is still limited. Purpose: This study investigated the prevalence, clinical features, causative agents, and mortality rate of ACDR with a type-IV hypersensitivity reaction among patients attending the Department of Dermatology and Venereology in Dr. Sardjito Hospital, Yogyakarta. Methods: This retrospective study was conducted examining medical records undertaken for five years (2011–2015). Of 68,375 patients medicated in the Department of Dermatology and Venereology, 397 patients were diagnosed as ACDR with a type-IV hypersensitivity reaction. Detailed history, including age, sex, past history, and family history of drug reaction taken by the patient, were obtained. Patch testing was done wherever feasible. Result: Of 68,375 patients, 397 patients were included in ACDR with type-IV hypersensitivity (0.58%), giving a 5% of mortality rate. The mean age of the patients was 40.42 years (±16.30; range 18 to 89 years). The female to male ratio was 1.1: 1. The Maculopapular rash was the most common ACDR manifestation (50.88%), followed by Stevens-Johnson Syndrome (13.85%), Fixed Drug Eruption (12.85%), and Drug Reaction with Eosinophilia and Systemic Symptoms (10.08%). The most common causative agents were beta-lactam (16.55%), NSAIDs (12.18%), and acetaminophen (8.62%). Conclusion:  Prescription of those drugs should be considered carefully so the incidence of ACDR can be reduced.
CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELLS THERAPY UNTUK PENYAKIT AUTOIMUN Roihan Mohamad Iqbal; Anindya Intan Ardanari; Muthia Fahiratunnisa Amany; Dyah Ayu Mira Oktarina
Essence of Scientific Medical Journal Vol 18 No 1 (2020): Volume 18 No. 1 (Januari - Juni 2020) Essential: Essence of Scientific Medical J
Publisher : Kelompok Ilmiah Hippocrates Fakultas Kedokteran Universitas Udayana

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.24843/ESTL.2020.v18.i01.p01

Abstract

Pendahuluan: Pemphigus vulgaris (PV) merupakan penyakit autoimun bolus kronis yang jarang ditemukan namun dapat berpotensi mengancam nyawa melalui adhesi protein autoantibodi desmoglein 3. Pengobatan PV yang paling sering digunakan saat ini adalah imunosupresan yang memiliki efek samping seperti peningkatan respon imun dan kemudian dapat kambuh kembali atau terjadi relapse. Oleh karena itu, dibutuhkan inovasi baru dalam pengobatan penyakit autoimun yang lebih spesifik dan dapat mencegah relaps pada jangka waktu yang lama.Tujuan penilitian ini adalah untuk melihat pengobatan terbaru yaitu penggunaan CAR T-cell dalam PV.Pembahasan : Pada pasien PV akan ditemukan adanya autoantibodi yang melawan desmoglein 3 (?Dsg3). ?Dsg3 sering ditemukan pada membran mukosa dan mucocutaneous. Aktivasi berlebih dari sel CD4+ Th2 menyebabkan adanya autoantibodi. CAR T-cell merupakan hasil dari rekayasi sel T yang dibantu vektor yang membawa reseptor chimera sesuai dengan yang ditargetkan . Pengobatan menggunakan CAR T-cell semakin menjanjikan setelah persetujuan FDA terhadap dua obat untuk kanker hematologi. Peneliti tertarik dalam mengembangkan CAR T-cell sebagai pengobatan penyakit autoimun. Hasil in vitro dari CAAR T-cell (modifikasi CAR T-cell) menunjukkan aktivitas sitotoksik sensitif melawan ?Dsg3 BCR. Hasil in vivo menunjukkan potensi terhadap eliminasi spesifik dari B cells Dsg3 berdasarkan serum dan sukses dalam mempertahankan intergritas epidermal pada tikus.Kesimpulan : CAR T-cell menunjukkan potensi sebagai pilihan terapi PV di masa depan. Akan tetapi, pengembangan dan penelitian lebih lanjut terhadap penggunaan CAR T-cell diperlukan untuk terapi PV sehingga dapat dihasilkan pilih pengobatan yang spesifik dengan efek samping minimum bagi pasien.